AI
CLDX icon

Atom Investors’s Celldex Therapeutics CLDX Stock Holding History

Atom Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,179
Closed -$893K – 638
2025
Q1 		$893K Buy
49,179
+9,976
+25% +$223K 0.11% 220
2024
Q4 		$991K Buy
+39,203
New +$1.07M 0.12% 240
2024
Q3 		– Sell
-52,164
Closed -$1.93M – 485
2024
Q2 		$1.93M Buy
52,164
+7,024
+16% +$265K 0.19% 164
2024
Q1 		$1.89M Buy
45,140
+4,258
+10% +$175K 0.24% 143
2023
Q4 		$1.62M Buy
+40,882
New +$1.2M 0.29% 119
2023
Q2 		– Sell
-5,698
Closed -$205K – 305
2023
Q1 		$205K Buy
+5,698
New +$246K 0.11% 209
2022
Q1 		– Sell
-10,781
Closed -$417K – 224
2021
Q4 		$417K Buy
+10,781
New +$470K 0.07% 181

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Atom Investors's CLDX Position: Q2 2025 in Review

Atom Investors sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 49,179 shares — an estimated $893K sold.

Atom Investors first reported a position in CLDX in Q4 2021 and held it in 7 quarters. The position peaked at $1.93M in Q2 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Atom Investors reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Atom Investors sold 49,179 Celldex Therapeutics shares in Q2 2025, an estimated $893K.
  • Atom Investors first reported a position in Celldex Therapeutics in Q4 2021 and held it in 7 quarters.
  • Atom Investors's Celldex Therapeutics position peaked at $1.93M in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Atom Investors's 13F filing for Q2 2025, filed 14 Aug 2025.